Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to -$118.1 million.

  • Collegium Pharmaceutical's Retained Earnings rose 3310.56% to -$118.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.1 million, marking a year-over-year increase of 3310.56%. This contributed to the annual value of -$164.0 million for FY2024, which is 2967.12% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Retained Earnings stood at -$118.1 million, which was up 3310.56% from -$149.6 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Retained Earnings peaked at -$118.1 million during Q3 2025, and registered a low of -$312.2 million during Q1 2021.
  • For the 5-year period, Collegium Pharmaceutical's Retained Earnings averaged around -$230.7 million, with its median value being -$239.4 million (2021).
  • Its Retained Earnings has fluctuated over the past 5 years, first crashed by 494761.72% in 2021, then surged by 3495.66% in 2024.
  • Collegium Pharmaceutical's Retained Earnings (Quarter) stood at -$256.3 million in 2021, then decreased by 9.75% to -$281.3 million in 2022, then increased by 17.12% to -$233.2 million in 2023, then increased by 29.67% to -$164.0 million in 2024, then increased by 27.99% to -$118.1 million in 2025.
  • Its last three reported values are -$118.1 million in Q3 2025, -$149.6 million for Q2 2025, and -$161.6 million during Q1 2025.